HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO MedSci Healthcare Holdings - The Investment Logic, the Business Analysis and the Risks

Pre IPO MedSci Healthcare Holdings - Some Points Worth the Attention

China Healthcare Weekly (Apr.21) - A Brutal Reality, Benign Returns from China Biotech, Pharmaron

Medlive Technology (2192.HK) - The Logic Has Shaken

Pre-IPO Huayiwang Technology - The Business Model Is Reasonable, but There Are Also Challenges

China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>The improvement of Medlive’s profitability in 22H1 seems more related to the large decreased income tax expense rather than any obvious improvement of main business or any other logic.</li>
<li>The single main business structure and insufficient core competitiveness add uncertainty to the Company's long-term prospects, which makes it difficult to significantly improve the valuation.</li>
<li>Medlive is under double pressure of "squeezing bubble" in healthcare industry and “the fading of traffic dividend” in Internet industry.Its growth logic/business model will be more scrutinized by the market.</li>
</ul>


The improvement of Medlive’s profitability in 22H1 seems more related to the large decreased income tax expense rather than any obvious improvement of main business or any other logic.
The single main business structure and insufficient core competitiveness add uncertainty to the Company's long-term prospects, which makes it difficult to significantly improve the valuation.
Medlive is under double pressure of "squeezing bubble" in healthcare industry and “the fading of traffic dividend” in Internet industry.Its growth logic/business model will be more scrutinized by the market.


Medlive Technology (2192.HK) 22H1- The Growth Logic/Business Model Is More Scrutinized by the Market